3 terminated, 2 completed, 2 recruiting, 1 unknown. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 3, Completed 2, Recruiting 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow BRAF Gene Mutation: new trials by email Literature Review of BRAF Gene Mutation trials Research Report on BRAF Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
| Continued Access to RXDX-105 RXDX-105 - Non Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2018-12-14 | 2025-05-15 |
| Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib - Melanoma, BRAF Gene Mutation | Phase 1 | Unknown | West Cancer Center | 4 | 2017-06-25 | 2020-10-12 |
| Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study - BRAF Gene Mutation, Hepatic Complication | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2013-08-23 | 2018-08-14 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
Carcinoma, Non-Small-Cell Lung (4) · Melanoma (4) · Colorectal Neoplasms (2) · Thyroid Neoplasms (2) · Brain Neoplasms (1) · Glioma (1) · Histiocytosis (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Renal Insufficiency (1)
Neoplasms (6) · Neoplasms by Site (6) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Skin Diseases (4) · Skin Neoplasms (4)
dabrafenib (3) · trametinib (2) · 130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Crizotinib (1) · Gemcitabine (1) · IFL protocol (1) · Panitumumab (1) · Pharmacogenomic Testing (1) · Sorafenib (1) · Vemurafenib (1) · agerafenib (1) · binimetinib (1) · encorafenib (1) · nilotinib (1)
Deciphera Pharmaceuticals, LLC (1) · Ikena Oncology (1) · Institut de Recherches Internationales Servier (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Rina Plattner (1) · West Cancer Center (1)
United States (8) · Australia (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Alexander Drilon, MD (1) · Caroline Germa, MD (1) · Filip Janku (1) · Ramesh Ramanathan (1) · Rina Plattner, PhD (1) · Ruta Arays, MD (1)
2025 (1), P30CA015083 (1), P30CA016672 (1), R01CA258751 (1), U01CA062490 (1), U01CA069912 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA186717 (1)